Chartwell Investment Partners LLC raised its position in shares of Merck & Co. (NYSE:MRK) by 0.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 316,795 shares of the company’s stock after buying an additional 130 shares during the period. Chartwell Investment Partners LLC’s holdings in Merck & Co. were worth $18,251,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MRK. Americafirst Capital Management LLC acquired a new stake in Merck & Co. during the second quarter worth about $115,000. NewSquare Capital LLC boosted its stake in Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock valued at $121,000 after buying an additional 261 shares during the last quarter. First New York Securities LLC NY purchased a new stake in Merck & Co. during the second quarter valued at $121,000. Lowe fs LLC boosted its stake in Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock valued at $151,000 after buying an additional 46 shares during the last quarter. Finally, JNBA Financial Advisors boosted its stake in Merck & Co. by 3.1% in the second quarter. JNBA Financial Advisors now owns 3,012 shares of the company’s stock valued at $174,000 after buying an additional 91 shares during the last quarter. 72.92% of the stock is owned by institutional investors.

Merck & Co. (NYSE:MRK) traded up 1.23% during midday trading on Wednesday, hitting $62.70. The company had a trading volume of 7,198,436 shares. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The firm has a market capitalization of $173.38 billion, a P/E ratio of 34.39 and a beta of 0.63. The firm’s 50 day moving average is $62.42 and its 200-day moving average is $57.54.

Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The business had revenue of $9.84 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the business earned $0.86 earnings per share. Merck & Co.’s revenue for the quarter was up .6% on a year-over-year basis. On average, equities research analysts expect that Merck & Co. will post $3.75 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 annualized dividend and a yield of 2.93%. Merck & Co.’s payout ratio is 101.10%.

MRK has been the subject of several research reports. Goldman Sachs Group Inc. reissued a “neutral” rating and set a $60.00 price target on shares of Merck & Co. in a report on Wednesday, June 8th. Argus reissued a “buy” rating on shares of Merck & Co. in a report on Thursday, June 9th. Jefferies Group dropped their price target on Merck & Co. from $54.00 to $53.00 and set a “hold” rating for the company in a report on Tuesday, June 14th. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price target on shares of Merck & Co. in a report on Tuesday, June 28th. Finally, Vetr raised Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price target for the company in a report on Monday, July 4th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of €63.31 ($70.34).

In other Merck & Co. news, insider Weir Mirian M. Graddick sold 30,000 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of €57.49 ($63.88), for a total transaction of €1,724,700.00 ($1,916,333.33). Following the sale, the insider now owns 162,151 shares in the company, valued at €9,322,060.99 ($10,357,845.54). The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Adam H. Schechter sold 50,000 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of €57.69 ($64.10), for a total value of €2,884,500.00 ($3,205,000.00). Following the sale, the executive vice president now owns 50,000 shares in the company, valued at approximately €2,884,500 ($3,205,000). The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

About Merck & Co.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.